Introduction: This retrospective cross-sectional observational study aimed to investigate the predictive value of the systemic immune-inflammation index (SII) for the progression of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).
Material and method: A total of 280 patients diagnosed with LUTS were analyzed, and their demographic characteristics, laboratory results, urological parameters, and SII levels were recorded retrospectively.
Results: Clinical progression of LUTS was observed in 43.2% of the patients, with 23.9% undergoing surgery and 21.4% progressing to acute urinary retention. The study found that elevated SII levels were significantly correlated with disease progression and worse outcomes. Multivariate analysis revealed that peak urinary flow rate, erectile function scores, and platelet levels were risk factors for predicting clinical progression in LUTS/BPH patients.
Conclusion: The findings suggest that systemic inflammation and immune dysregulation play a role in BPH pathogenesis and the development of LUTS. Incorporating SII assessment into routine clinical practice could aid in risk stratification, treatment decision-making, and monitoring of disease progression in LUTS/BPH patients.
Keywords: Clinical progression; Inflammatory markers; Systemic immune-inflammation index; benign prostatic hyperplasia; lower urinary tract symptoms.